Neuralstem Raises $19.6M in a Stock Offering to Support ALS Therapy Through Phase II

Neuralstem’s Phase II trial in ALS will likely get a boost in funding through their recent $19.6M stock offering. Neuralstem, which received financial support from the National Institutes of Health and from the ALS Association for the Phase II study, is testing their spinal cord-derived neural stem cells (called NSI-566) in ALS patients. The cells are injected at various segments of the spinal cord to integrate into the motor neuronal circuitry. Interim results from the Phase I study led by Dr. Eva Feldman were published. The Phase II study is aimed at identifying the maximal-safe tolerated dose of the treatment, and the trial is expected to be completed in late 2014.

Click here to read the full story.

Share this: